Ching-Hon Pui, MD, Kjeld Schmiegelow, MD, and Lori Muffly, MD, MS
In this segment, “New Developments in ALL”, Ching-Hon Pui, MD, Kjeld Schmiegelow, MD, and Lori Muffly, MD, MS discuss prognostic and therapeutic advances, such as immune- and cellular therapies.
Next generation sequencing has identified novel somatic genetic abnormalities with prognostic and therapeutic implications. Deep sequencing techniques might be used to identify highly curable patients. Hopefully, such patients could be cured upfront without the need of continuation therapy. Areas of clinical development include CAR-T cell therapy, novel therapies, and the role of minimal residual disease.